Category: GLP-1s

In early October, the FDA announced that the two-year shortages of Mounjaro and Zepbound were resolved. After pushback from compounding pharmacies, the agency reaffirmed the decision on Dec. 19. 

The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a November report from HHS.

A preprint study confirmed an association between Ozempic’s active ingredient and an increased — but overall low — risk of vision loss. 

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound.

Alaska recorded the highest percentage of medication fills for weight loss drugs this year, according to data from GoodRx. 

Medication fills for weight loss drugs such as Zepbound and Wegovy rose sharply this year, despite high out-of-pocket costs for patients, according to a Dec. 5 analysis from GoodRx.

Should employers, patients, or insurers bear the largest share of an annual $411 billion cost?

The White House is pitching broader coverage of weight loss drugs for millions of Americans on Medicare and Medicaid.

The battle over who should provide obesity and diabetes drugs like Ozempic and Wegovy has reached a critical point, as manufacturers and compounding pharmacies clash over the demand of these medications, NPR reported Nov. 20.